Analysts think Stada is too expensive

It seems Stada 's stock price too high now. The majority of the analysts estimate Stada is currently overpriced. The recommendations are: 5 times sell, 4 times hold and no buys. The average of the target prices for the stock equals 66,68 euros. This is around 21 percent less than the current price of 84,28 euros.

Estimates for Stada wide spread

Over the current book year the total revenue will be 2,43 billion euros (consensus estimates). This is slightly more than 2016's revenue of 2,31 billion euros.

Historical revenues and results Stada plus estimates 2018

The analysts expect for 2018 a net profit of 224 million euros. For this year most of the analysts expect a profit per share of 3,61 euros. Based on this the price/earnings-ratio is 23,35.

Per share the analysts expect a dividend of 0,85 cents per share. Thus the dividend yield equals 1,01 percent. The average dividend yield of the pharmaceutical companies is a moderate 1 percent.

Recent target prices around 73 euros

The most recent recommendations for the pharmaceutical company are from DZ Bank, Independent Research and M.M. Warburg & Co..

Stada 's market capitalization is based on the number of outstanding shares around 5,25 billion euros.

Historical stock prices Stada

At 17.36 the stock trades 0,1 percent higher at 84,28 euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.